| Primary information |
|---|
| sequence ID | Seq_1270 |
| Peptide sequence | DGESGRPGRPGERGLPGPPG |
| CancerPDF_ID | CancerPDF_ID10850, CancerPDF_ID10851, |
| PMID | 21805675,21805675 |
| Protein Name | Collagen alpha-1(III) chain,Collagen alpha-1(III) chain |
| UniprotKB Entry Name | CO3A1_HUMAN,CO3A1_HUMAN |
| Fluid | Urine,Urine |
| M/Z | 1992.9404,2008.9332 |
| Charge | NA,NA |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | MALDI-TOF-MS,MALDI-TOF-MS |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | 1,1 |
| CancerPDF_ID | CancerPDF_ID10850, CancerPDF_ID10851, |
| p-Value | NA,NA |
| Software | NA,NA |
| Length | 20,20 |
| Cancer Type | Muscle-invasive bladder cancer,Muscle-invasive bladder cancer |
| Database | SwissProt Database,SwissProt Database |
| Modification | "Oxidation: 10, 16, 19","Oxidation: 7, 10, 16, 19" |
| Number of Patients | 751 bladder cancer and 127 control,751 bladder cancer and 127 control |
| Regulation | Differentially expressed between cancer vs normal samples,Differentially expressed between cancer vs normal samples |
| Validation | Mann-Whitney tests and areas under receiver-operator characteristic,Mann-Whitney tests and areas under receiver-operator characteristic |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |
| Primary information |
|---|
| sequence ID | Seq_1272 |
| Peptide sequence | DGESGRpGRpGERGLpGPpG |
| CancerPDF_ID | CancerPDF_ID3412, |
| PMID | 21591268 |
| Protein Name | Collagen alpha-1(III) chain |
| UniprotKB Entry Name | CO3A1_HUMAN |
| Fluid | Urine |
| fdr | 2007.95 |
| Profiling Technique | CE-MS-TOF |
| Peptide Identification technique | MS/MS |
| Labelled/Label Free | Label Free |
| CancerPDF_ID | CancerPDF_ID3412, |
| p-Value | NA |
| Software | MASCOT |
| Length | 20 |
| Cancer Type | Bladder cancer |
| Database | SwissProt protein database |
| Modification | p:Hydroxy-Proline |
| Number of Patients | 334 Patients |
| Regulation | Upregulated in cancer vs normal |
| Validation | Cross-validation |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| Peptide Atlas | NA |
| IEDB | NA |